BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33300603)

  • 1. Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Shi Z; Wei J; Na R; Resurreccion WK; Zheng SL; Hulick PJ; Helfand BT; Talamonti MS; Xu J
    Int J Cancer; 2021 Apr; 148(7):1658-1664. PubMed ID: 33300603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator.
    Jourdain ML; Sergheraert J; Braux J; Guillaume C; Gangloff SC; Hubert D; Velard F; Jacquot J
    Biochim Biophys Acta Mol Basis Dis; 2021 Mar; 1867(3):166010. PubMed ID: 33188942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population.
    Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M
    Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
    Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation.
    Le Henaff C; Gimenez A; Haÿ E; Marty C; Marie P; Jacquot J
    Am J Pathol; 2012 May; 180(5):2068-75. PubMed ID: 22449949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
    Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
    Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population screening of F508del (DeltaF508), the most frequent mutation in the CFTR gene associated with cystic fibrosis in Argentina.
    Roqué M; Godoy CP; Castellanos M; Pusiol E; Mayorga LS
    Hum Mutat; 2001 Aug; 18(2):167. PubMed ID: 11462248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of a cystic fibrosis carrier testing clinic for couples.
    Christie LM; Ingrey AJ; Turner GM; Proos AL; Watts GE
    Med J Aust; 2009 Nov; 191(9):499-501. PubMed ID: 19883345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis.
    Ramalho AS; Beck S; Meyer M; Penque D; Cutting GR; Amaral MD
    Am J Respir Cell Mol Biol; 2002 Nov; 27(5):619-27. PubMed ID: 12397022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Fibrosis, CFTR, and Colorectal Cancer.
    Scott P; Anderson K; Singhania M; Cormier R
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced F508del-CFTR channel activity ameliorates bone pathology in murine cystic fibrosis.
    Le Henaff C; Haÿ E; Velard F; Marty C; Tabary O; Marie PJ; Jacquot JP
    Am J Pathol; 2014 Apr; 184(4):1132-1141. PubMed ID: 24529904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the cystic fibrosis mutation F508del-CFTR on renal cyst formation and growth.
    Li H; Yang W; Mendes F; Amaral MD; Sheppard DN
    Am J Physiol Renal Physiol; 2012 Oct; 303(8):F1176-86. PubMed ID: 22874761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.